AstraZeneca Bristol Myers Squibb merger proposal

Reports emerged of a potential $400 billion merger between AstraZeneca and Bristol Myers Squibb, prompting investor concerns over patent cliffs and antitrust risks. A senior source subsequently denied the two companies were ever in substantive merger talks.